300 related articles for article (PubMed ID: 29986086)
1. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
López-Cortés LF; Trujillo-Rodríguez M; Báez-Palomo A; Benmarzouk-Hidalgo OJ; Dominguez-Molina B; Milanés-Guisado Y; Espinosa N; Viciana P; Gutiérrez-Valencia A
J Infect Dis; 2018 Jul; 218(4):624-632. PubMed ID: 29986086
[TBL] [Abstract][Full Text] [Related]
2. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
[TBL] [Abstract][Full Text] [Related]
3. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
4. Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis.
Girón-Ortega JA; Márquez-Coello M; Gutiérrez-Saborido D; Arizcorreta A; Cuesta-Sancho S; Girón-González JA
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1863-1871. PubMed ID: 33822285
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B;
AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
[TBL] [Abstract][Full Text] [Related]
7. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients.
Medrano LM; Garcia-Broncano P; Berenguer J; González-García J; Jiménez-Sousa MÁ; Guardiola JM; Crespo M; Quereda C; Sanz J; Canorea I; Carrero A; Hontañón V; Muñoz-Fernández MÁ; Resino S;
AIDS; 2018 Jun; 32(9):1095-1105. PubMed ID: 29438197
[TBL] [Abstract][Full Text] [Related]
8. Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy.
Gutiérrez-Saborido D; Gutiérrez-Valencia A; González Domenech CM; López Ruz MÁ; Raffo Márquez M; Omar M; Girón-González JA;
Ann Hematol; 2019 Aug; 98(8):1953-1959. PubMed ID: 31025161
[TBL] [Abstract][Full Text] [Related]
9. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
[TBL] [Abstract][Full Text] [Related]
10. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
[TBL] [Abstract][Full Text] [Related]
11. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study.
Garcia-Broncano P; Medrano LM; Berenguer J; Brochado-Kith O; González-García J; Jiménez-Sousa MÁ; Quereda C; Sanz J; Téllez MJ; Díaz L; JIménez JL; Resino S;
J Infect; 2020 Jan; 80(1):99-110. PubMed ID: 31585189
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CD4⁺ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients.
Hodowanec AC; Brady KE; Gao W; Kincaid SL; Plants J; Bahk M; Landay AL; Huhn GD
J Acquir Immune Defic Syndr; 2013 Nov; 64(3):232-40. PubMed ID: 24131865
[TBL] [Abstract][Full Text] [Related]
15. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
[TBL] [Abstract][Full Text] [Related]
16. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
[TBL] [Abstract][Full Text] [Related]
17. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
18. Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection.
Shmagel KV; Saidakova EV; Shmagel NG; Korolevskaya LB; Chereshnev VA; Robinson J; Grivel JC; Douek DC; Margolis L; Anthony DD; Lederman MM
HIV Med; 2016 Sep; 17(8):581-9. PubMed ID: 27187749
[TBL] [Abstract][Full Text] [Related]
19. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.
Abad-Fernández M; Vallejo A; Hernández-Novoa B; Díaz L; Gutiérrez C; Madrid N; Muñoz MA; Moreno S
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):149-53. PubMed ID: 24047967
[TBL] [Abstract][Full Text] [Related]
20. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]